PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma

Individual experimental treatment attempt at Hopp Children's Cancer Center Heidelberg (KiTZ) and Heidelberg University Hospital (UKHD) using a TCR T-cell therapy engineered with a PRAME-directed TCR provided by Immatics 17-year-old adolescent with bulky, rapidly progressing nephroblastoma and no remaining treatment options achieved deep remission, including marked regression of liver, lung and brain metastases; response ongoing at 6 months of follow-up PRAME is a multi-pediatric cancer target, and findings highlight the therapeutic potential of PRAME TCR T-cell therapy in pediatric patients with solid tumorsData will be presented in a late-breaking poster at the AACR Annual Meeting 2026 by Dr.